Simple Summary Multiple myeloma is a plasma cell disorder that accounts for around 10%
of all haematological malignancies. This neoplasia is often associated with a significant …

ABSTRACT Introduction Multiple Myeloma (MM) is hematological neoplasia originating from
plasma cells, which accounts for almost 1% of all oncologic malignancies. The median age …

Introduction Common manifestations of multiple myeloma include osteolytic lesions,
cytopenias, hypercalcemia, and renal insufficiency. Patients may also exhibit heart failure …

We report here a case of a 57-year-old man with multiple myeloma and high-output cardiac
failure (HOCF), which completely resolved upon treatment of his myeloma. Recurrence of …

Multiple myeloma (MM) is a plasma cell malignancy that accounts for 10% of hematological
cancers. It predominantly affects elderly people; median age at diagnosis is 70 years …

It has been known for some time that some oncologic drugs can cause heart damage. The
term 'cardiotoxicity'just refers to the presence of a cardiac event during therapy or at least …

With the continuous improvement in survival of cancer patients, including those with multiple
myeloma, related to the novel treatment agents and therapeutic approaches, the probability …

Abstract Purpose of Review Multiple myeloma is a common hematologic malignancy
characterized by recurrent relapsing disease course requiring use of various therapies. Over …

Purpose of review Multiple myeloma treatment regimens consist of proteasome inhibitors
(bortezomib, carfilzomib, and ixazomib), immunomodulatory drugs (thalidomide …

Cardiovascular disease in patients with multiple myeloma may derive from factors unrelated
to the disease (age, diabetes, dyslipidemia, obesity, prior cardiovascular diseases), related …